European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume 22, Issue 2, Pages 196-213
Publisher
Wiley
Online
2019-12-09
DOI
10.1002/ejhf.1673
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
- (2019) Darren K. McGuire et al. CIRCULATION
- A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
- (2019) John J.V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline
- (2019) James Januzzi et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program
- (2019) Gemma A. Figtree et al. CIRCULATION
- Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial
- (2019) Remo H. M. Furtado et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology
- (2019) Petar M. Seferovic et al. EUROPEAN JOURNAL OF HEART FAILURE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
- (2019) Thomas R Pieber et al. Lancet Diabetes & Endocrinology
- Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
- (2019) Subodh Verma et al. CIRCULATION
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- (2018) Beatrice C. Lupsa et al. DIABETOLOGIA
- Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
- (2018) Franco Cosmi et al. EUROPEAN JOURNAL OF HEART FAILURE
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
- (2018) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- SGLT-2 Inhibitors and Cardiovascular Risk
- (2018) Matthew A. Cavender et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study
- (2018) Michael R. Cobretti et al. PHARMACOTHERAPY
- Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers
- (2018) Lili Tong et al. POSTGRADUATE MEDICINE
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Association Between Type 2 Diabetes and All-Cause Hospitalization and Mortality in the UK General Heart Failure Population
- (2018) Claire A. Lawson et al. JACC-Heart Failure
- Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure
- (2018) John J.V. McMurray et al. JACC-Heart Failure
- OUP accepted manuscript
- (2018) EUROPEAN HEART JOURNAL
- SGLT1 inhibition: Pros and cons
- (2018) Vasilis Tsimihodimos et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Empagliflozin directly improves diastolic function in human heart failure
- (2018) Steffen Pabel et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- (2018) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction
- (2018) Andrija Pavlović et al. European Journal of Preventive Cardiology
- The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors
- (2017) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
- (2017) Bernard Zinman et al. STROKE
- Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post‐Hoc Analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial
- (2017) Marco Dauriz et al. Journal of the American Heart Association
- Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
- (2017) Christianne L. Roumie et al. Journal of the American Heart Association
- Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE
- (2016) Søren L. Kristensen et al. Circulation-Heart Failure
- Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
- (2016) Subodh Verma et al. DIABETES CARE
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry
- (2016) Giovanni Targher et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes
- (2016) David H. Fitchett et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2016) Piotr Ponikowski et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials
- (2016) J. Kongwatcharapong et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care
- (2016) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
- (2016) Ling Li et al. BMJ-British Medical Journal
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) et al. European Journal of Preventive Cardiology
- Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care
- (2016) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
- (2016) Ling Li et al. BMJ-British Medical Journal
- Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- (2016) John J. Lepore et al. JACC-Heart Failure
- Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2015) Ronan Roussel et al. ADVANCES IN THERAPY
- Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
- (2015) Xiao-Wu Chen et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial
- (2015) Michel Komajda et al. EUROPEAN JOURNAL OF HEART FAILURE
- Mean HbA1cand mortality in diabetic individuals with heart failure: a population cohort study
- (2015) Douglas H.J. Elder et al. EUROPEAN JOURNAL OF HEART FAILURE
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
- (2014) Francisco Kerr Saraiva et al. Cardiovascular Diabetology
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Hemoglobin A1c, comorbid conditions and all-cause mortality in older patients with diabetes: A retrospective 9-year cohort study
- (2014) David Grembowski et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
- (2014) Michael Nauck Drug Design Development and Therapy
- Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure
- (2013) Dean T. Eurich et al. Circulation-Heart Failure
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypo- and Hyperglycemia Predict Outcome in Patients With Left Ventricular Dysfunction After Acute Myocardial Infarction: Data From EPHESUS
- (2012) Christian Ukena et al. JOURNAL OF CARDIAC FAILURE
- Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus
- (2011) Adrian V. Hernandez et al. American Journal of Cardiovascular Drugs
- Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation
- (2011) Alvaro Alonso et al. CIRCULATION
- Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus
- (2010) Josie M.M. Evans et al. AMERICAN JOURNAL OF CARDIOLOGY
- Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure
- (2010) David Aguilar et al. Circulation-Heart Failure
- Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
- (2010) M. Komajda et al. EUROPEAN HEART JOURNAL
- Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus
- (2009) K M Goode et al. HEART
- Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and Diabetes
- (2009) Digish D. Shah et al. JOURNAL OF CARDIAC FAILURE
- Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes
- (2009) David Aguilar et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure
- (2008) Hertzel C. Gerstein ARCHIVES OF INTERNAL MEDICINE
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
- (2008) M. R. MacDonald et al. EUROPEAN HEART JOURNAL
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Renal and Vascular Mechanisms of Thiazolidinedione-Induced Fluid Retention
- (2008) Tianxin Yang et al. PPAR Research
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started